Navigation Links
Alternatives Available Nationwide to Addictive Benzodiazepines for Anxiety
Date:1/2/2017

BIRMINGHAM, Ala., Jan. 2, 2017 /PRNewswire/ -- The pharmaceutical research company TPD LLC (Trends in Pharma Development) announced that the PanX® new class of medicines intended for the treatment of anxiety are now available nationwide as prescription compounded drugs.

Two US patents 9,446,030 and 9,517,231 were recently issued to the company in September and December, respectively.  The patents broadly cover dual drug combinations of historically-safe active ingredients that are being re-purposed for the treatment of anxiety disorders, such as social anxiety disorder, panic, and PTSD. The combinations were designed to suppress the multiple symptoms of acute anxiety.

The PanX® drugs are intended as "as needed" alternatives to benzodiazepines (e.g., Xanax® or Valium®) that are addictive, have the potential for abuse, and are Controlled Substances.  However, the active ingredients in the PanX® brand, beta blockers and antiemetic motion sickness agents, have no history of addiction or abuse in five decades of prescription or over-the-counter use.  The company's goal for the patented new class of medicines is to provide effective, fast-acting, yet safer alternatives to benzodiazepines.

According to a leading authority on anxiety therapies, Professor Charles B. Nemeroff, MD PhD, Chairman of the Department of Psychiatry and Behavioral Sciences at the University of Miami, "A number of patients with prominent anxiety symptoms do not respond or cannot tolerate currently available treatments. This novel approach combining two medications with distinct mechanisms of action has the potential to fill an important niche in the management of such patients."

TPD has contracted with Pine Pharmaceuticals and Pine Pharmacy of New York, and Custom Meds of Florida to produce the products as prescription compounded drugs.  The combination drug products are available in 49 states as patient-specific prescriptions by mail order and/or as "office use" medications administered by physicians, for instance in medical procedures when patients are anxious or fearful.  For additional information see www.PanX.us.

TPD is also pursuing the clinical development of selected PanX® drugs to seek product approval by the US Food and Drug Administration (FDA).

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alternatives-available-nationwide-to-addictive-benzodiazepines-for-anxiety-300384404.html


'/>"/>
SOURCE TPD LLC
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. RI Physical Therapist Discusses Alternatives to Rising Opioid Use
2. EpiBiome Secures $6 Million Series A Financing to Develop Alternatives to Small-Molecule Antibiotics for Agriculture
3. KaloBios to Reduce Workforce, Explore Strategic Alternatives
4. The Manufacturer of the SynCardia Total Artificial Heart has Hired Investment Bank Canaccord Genuity, Inc. to Advise the BOD on Strategic Alternatives to Maximize Stakeholder Equity
5. Unilife Announces Review of Strategic Alternatives
6. As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation
7. Pessaries and Other Vaginal Mesh Alternatives Discussed by Life Care Solutions Group
8. BioNet Received Thai FDA Approval of the Worlds Only Available Recombinant Monovalent Acellular Pertussis (aP) Vaccine
9. Cologuard Available to Humana Members as In-Network Colon Cancer Screening Option
10. Zymo Research Announces Nucleic Acid Purification Kits Now Available on Amazon.com
11. In-home PFT Testing Is Now Available to Patients with ndd Medicals Mobile EasyOne Pro
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally ... care, have expanded their existing home health joint venture through an agreement, effective ... operating a joint venture home health company with Asante, delivering clinically integrated care, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
Breaking Medicine News(10 mins):